News & events
Get to Know Us
March 23, 2021
Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC)
July 9, 2020
Unconventional Weapon in the War on Cancer Revealed
June 10, 2019
Immunicom Announces First Patient Enrollment in Multi-Center, Triple-Negative Breast Cancer Clinical Trial
May 14, 2018
Immunicom’s Immunotherapy Product Receives U.S. FDA Breakthrough Device Designation for the Treatment of Cancer
Press Releases
April 30, 2021
Immunicom Presents Promising Preliminary Data from Multiple Studies in Late-Stage Cancer Patients at ISFA / E-ISFA Conference
April 21, 2021
Immunicom Recognized as One of the Best Places to Work in the U.S.
March 26, 2021
Oncology Investors to Hear “Cancer Device Company of the Year” Immunicom Present at MedInvest Conference
March 23, 2021
Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC)
In the news
December 1, 2020
StartUpCity’s Global “Ten Most Promising 2020 Biotech Startups”
July 9, 2020
Jerusalem Post – Sheba Launches World’s First ‘Reversed Personalized Medicine’ Cancer Trial
December 31, 2018
Journal of Translational Medicine: “Unleashing Endogenous TNF-alpha as a cancer immunotherapeutic”
Get in touch today
Let’s talk about what we can achieve together
Learn more about
our team
our team